公开(公告)号：US20190125796A1

公开(公告)日：2019-05-02

申请号：US16095791

申请日：2017-04-28

Applicant: MUSC Foundation for Research Development

Inventor： Shikhar Mehrotra ,  Michael I. Nishimura ,  Pravin Kesarwani ,  Shilpak Chatterjee

IPC: A61K35/17 ,  C12N5/0783 ,  A61P35/00 ,  A61K38/20 ,  A61K38/06 ,  A61K31/381 ,  A61K31/401 ,  A61K38/43

Abstract: The present invention relates to an adoptive T cell therapy using cells generated by genetically or biochemically reprogramming T cells to produce T memory stem cells (Tscm) that persist longer in vivo and are superior anti-tumor effector cells.

公开(公告)号：US20230025360A1

公开(公告)日：2023-01-26

申请号：US17817125

申请日：2022-08-03

Applicant: MUSC Foundation for Research Development

Inventor： Shikhar Mehrotra ,  Pravin Kesarwani ,  Shilpak Chatterjee

IPC: A61K35/17 ,  A61P35/00 ,  A61K31/381 ,  A61K31/401 ,  A61K38/06 ,  A61K38/20 ,  A61K38/43 ,  C12N5/0783

Abstract: The present invention relates to an adoptive T cell therapy using cells generated by genetically or biochemically reprogramming T cells to produce T memory stem cells (Tscm) that persist longer in vivo and are superior anti-tumor effector cells.

公开(公告)号：US11883430B2

公开(公告)日：2024-01-30

申请号：US16347743

申请日：2017-11-08

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Shikhar Mehrotra ,  Shilpak Chatterjee

IPC: A61K35/17 ,  A61P35/00 ,  A61K35/26 ,  C07K16/24 ,  C12N5/0783 ,  A61K45/06 ,  A61K9/00 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395

CPC classification number: A61K35/17 ,  A61K9/0019 ,  A61K35/26 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K16/249 ,  C07K16/2896 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C07K2317/55 ,  C07K2317/76 ,  C12N2501/15 ,  C12N2501/2301 ,  C12N2501/2306 ,  C12N2501/2312 ,  C12N2501/2323 ,  C12N2501/599 ,  A61K39/39558 ,  A61K2300/00

Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.